ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
NanoVelos Logo

NanoVelos

Our dextran drug delivery system was first developed at the Faculty of Chemical and Process Engineering of the Warsaw University of Technology in the Biomedical Engineering Laboratory established by Dr. Ciach decided to commercialize the technology and founded NanoVelos. Technology based on polysaccharide nanoparticles is orginal solution patented by NanoVelos SA In vitro experiments: Assesment of cell viability (MTT assay, HeLa cells etc.) demonstrates that examined drugs released from nanoparticles retains its potential to induce cell death. The main goals of those studies is to collect the data providing submission to FDA or EMA. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants’ behavior, such as diet. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives. The EMA (European Medicines Agency), is the European Union’s equivalent to the U.S. Treatments are not one-size-fits-all, that’s why we focus on various areas.

Quick overview

Warsaw, Poland

Founded in 2013

1-10 Employees

Additional information

Working industry

Pharmaceuticals

Type of company

Manufacturer, Service provider

Ownership structure

Privately Held

Locations

1 Headquarter

Number of services

2 Services

Specialised areas

nanotechnology, drug nanodelivery, supergenerics, Delivery, Pharmaceuticals, Pharmaceutical, oncology, Health Care

Products & services of NanoVelos

NanoVelos offers a wide range of products and services

Product: Our Services in Nanotechnology | NanoVelos | Drug Delivery Systems

Service

Our Services in Nanotechnology | NanoVelos | Drug Delivery Systems

Go to product >

Product: Our services PL | NanoVelos | Drug Delivery Systems

Service

Our services PL | NanoVelos | Drug Delivery Systems

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

Poland


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

B

Grade (A-E)

View details

Social

B

Grade (A-E)

View details

Governance

B

Grade (A-E)

View details

Use Cases of NanoVelos

Get insights into the use cases of NanoVelos

UseCase: Projects | NanoVelos | Drug Delivery Systems

Use case

Projects | NanoVelos | Drug Delivery Systems

Partners Grants Preclinical and clinical studies of innovative nanoformulations of anticancer drugs POIR.01.01.01-00-0021/16-00 In this project NanoVelos plans to carry out industrial research aimed at encapsulation of number of chemotherapeutic agents used already in a clinic into proprietary nanoparticles. Of the newly synthesized nanoformulations we will select those which will …

Headquarter of NanoVelos

NanoVelos operates in 1 country around the world

City: Warsaw

State: Masovian Voivodeship

Country: Poland

Locations of NanoVelos

Get an overview of the locations of NanoVelos

Location

Country

State

City

Headquarter

Poland

Masovian Voivodeship

Warsaw

Frequently asked questions (FAQ) about NanoVelos

Some frequent questions that have been asked about NanoVelos

The company headquarter of NanoVelos is located in Warsaw, Masovian Voivodeship, Poland. It's worth noting, that the company may have more locations

As of the latest available information NanoVelos has around 1-10 employees worldwide.

NanoVelos was founded in 2013

The company NanoVelos has it's main focus in the industries of Pharmaceuticals

Competitors of NanoVelos

Check out some interesting alternative companies to NanoVelos

Optima Nanomed Limited's Logo

Optima Nanomed Limited

London, United Kingdom

1-10 Employees

-

We are re-imagining and re-shaping drug delivery by commercialising top-notch principles from academia, minimising drug development costs and time to market; and eliminating side effects. We are developing nanomaterials for improved drug delivery into tissues that hard to target and penetrate by conventional drugs and methods. We are leveraging from years of experience and expertise. We are using proprietary technology to develop smart programmable nanomaterials. An inevitable outcome of taking a drug are side effects due to poor drug delivery - an example are cancer patients who often lose their hair even their lives! Because the drug is poorly delivered to both healthy and cancer cells leading to toxicity. Poor drug delivery leads to toxicity, side effects, the need of higher dosages and major capital losses. At Optima Nanomed we believe now is the time to act.

AQUA Biomaterials's Logo

AQUA Biomaterials

San Diego, United States

1-10 Employees

2014

This product is the next generation, animal-free version of the heparin nanoparticles Dr. Drug Delivery - small molecule, DNA/RNA, antibody, conjugates and fragments. Objective: Develop system to deliver large, hydrophilic molecules such as hyaluronic acid into human skin. Diffusion coefficient of hyaluronic acid enhanced 2.5-fold in (+/+) over current marketed products (O/W and -/+). Our technology delivers more hyaluronic acid to the skin than what is lost on a daily basis. Conclusion: A transdermal delivery nanotechnology has been developed in which the diffusion of the molecule through the stratum corneum is dependent on the diameter of the internal phase nanogel, not on the molecular weight of the individual molecule. We offer contract services to customers who seek expert technical advice, product prototyping, and process development for projects including:. We also manage early stage research and development projects through pilot production and pre-clinical testing.

Westwood Bioscience Inc's Logo

Westwood Bioscience Inc

Los Angeles, United States

1-10 Employees

2018

Nanomedicine is a newly evolving field in which the functions and features of nanoscale objects and systems are used for improved diagnostics, imaging, therapeutics and regenerative medicine.Nanotherapeutics include the use of nanocarriers for drug delivery, with the potential to improve the pharmacokinetics, biodistribution, tissue concentrations and efficacy over the free drug. In addition, encapsulated drug delivery can also reduce the systemic biodistribution and toxicity of potentially hazardous drugs such as chemotherapeutics.The Silicasome is an example of an encapsulated nanocarrier, which is comprised of a mesoporous silica nanoparticle core with a lot of drug packaging space, and surrounded by a lipid bilayer. Westwood Bioscience, Inc., incorporated in 2017, are developing a new nanocarrier technology for improved delivery of chemotherapeutic agents to pancreas and colon cancer tuned to achieve improved efficacy, while reducing toxicity.Work led by Drs. This development has attracted significant attention in the field of pancreas cancer chemotherapy, as the Westwood nanocarrier is capable of delivering a single or ratiometric combination of chemotherapeutic agents to the cancer site, with the ability to overcome the drug resistant in stroma, improve efficacy and improve the toxicity over other nanocarriers used for treating this disease.

NanoSiliCal Devices Srl's Logo

NanoSiliCal Devices Srl

Rende, Italy

1-10 Employees

2014

We produce highly intelligent, multifunctional, mesoporous silica micro and nano-systems to be exploited in target therapy. Our products technology is based on science of materials, providing nanostructured particles that can be administered intravenously, and, through the bloodstream, they can reach cancer cells, interact with them through a biological process and release a drug within. NanoSiliCal Devices is a spin-off at the University of Calabria, founded in 2014 by the research team made up by Prof. It aims to develop nanostructured products that may be exploited as smart anticancer therapies, basing its activities on the results of experimental studies, gained in the last 10 years, that haveled to several International Patent Applications and publications on international journals with high impact factor. Research and development activities are the aim of the innovative nature of NanoSiliCal Devices. NanoSiliCal Devices is the result of several studies based on properties, synthesis, characterization and biological validation of mesoporous silicas.These studies involve a modular method of synthesis of mesoporous silica based micro-and nano-systems that could be used for drug delivery. This is an excellent drug delivery system based on Receptor-specific ligand on the external surface and drug inside the pores. The main application of our products is the targeted chemotherapy, whose main purpose is to reduce drug doses, to improve therapeutic efficacy and to reduce toxic and side effects.

Nanoform's Logo

Nanoform

Helsinki, Finland

11-50 Employees

2015

Nanoform works to improve the lives of patients globally by overcoming drug development and delivery challenges through our game-changing technologies and novel formulation capabilities. We have a dedicated, multi-disciplinary team with a combined experience of launching 100+ medicines. TargTex Ceo João Seixas discusses the value Nanoform’s CESS® technology delivered for TargTex’s drug candidate targeting glioblastoma. At Nanoform, we are proud to reflect our dedication to sustainability in our cutting-edge nanoparticle engineering processes. Discover how we are driving sustainability in the pharma industry in our Ebook.

DelSiTech Ltd's Logo

DelSiTech Ltd

Turku, Finland

11-50 Employees

2001

DelSiTech is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biopharmaceuticals and viral vectors. DelSiTech currently holds technology collaboration and licensing agreements with AstraZenega, Anticancer Bioscience, Bayer Pharma AG, Innovare R&D, Iveric Bio, Optifye Therapeutics, Unitaid, MedImmune and Solani Therapeutics Ltd and evaluation agreements with several pharma, animal health and biotech companies. We focus on parenteral and local administration of drug products. Products with high commercial potential – DelSiTech’s own drug product for high unmet clinical and commercial needs. Innovative delivery technology – Silica-based drug delivery for controlled release of small molecules and bioparmaceuticals. New nanotech solutions in drug delivery – DelSiTech is a world technology leader in advanced biodegradable silica based controlled release materials. The natural solution for your drug delivery needs – We help you to get the most out of your innovations. The preferred method for controlled delivery of small molecule drugs, including poorly or highly soluble compounds.